Product Development

BioCentury Commentary

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Moving Beyond a Buzzword: How small- to mid-sized biotechs can adopt patient centricity in oncology trials</h1><h2 class="title-bottom webtitle">Guest Commentary: Even small steps toward patient engagement can improve cancer trial recruitment, reduce costs</h2><div class="byline">Lucy Clossick Thomson, Senior Director of Oncology Project Management, and Susan Campbell, Director of Patient Recruitment, <a href="https://profiles.biocentury.com/companies/icon_plc">ICON plc</a></div><div class="date"></div> </div></div></div>

ICON plc

U.S. Food and Drug Administration (FDA)

clinical trial design

patient engagement

recruitment

Moving Beyond a Buzzword: How small- to mid-sized biotechs can adopt patient centricity in oncology trials

Guest Commentary: Even small steps toward patient engagement can improve cancer trial recruitment and reduce costs.

Guest Commentary: Even small steps toward patient engagement can improve cancer trial recruitment, reduce costs

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>